Compounded GLP-1 sits at less than a third of the branded price. Whether that price difference is a smart trade-off in 2026 depends on three things most patients do not learn until after they start: pharmacy verification, formulation differences, and the FDA shortage timeline.
The short answer
Compounded semaglutide and tirzepatide from a properly licensed 503A pharmacy contain the same active molecule as the branded versions. The clinical efficacy data is more limited than the branded trials, but real-world outcomes from our reader survey track close to branded outcomes for most patients. The two genuine risks are pharmacy quality variability and the looming end of legal compounding once the FDA shortage list status changes.
What “compounded” means
A compounded medication is one prepared by a licensed pharmacy from raw active pharmaceutical ingredient (API), customized for an individual patient’s prescription. 503A pharmacies are state-licensed and prepare individualized prescriptions; 503B outsourcing facilities operate at larger scale under federal oversight.
Compounded GLP-1 only became broadly available because semaglutide and tirzepatide have been on the FDA drug shortage list, which legally permits 503A pharmacies to compound copies of medications normally protected from compounding.
Is it equivalent?
The active molecule is the same. The differences that matter:
- Formulation. Some compounded versions include B12, B6, or amino acids in the same vial. The clinical effect of these additions is debated.
- Concentration. Compounded versions are sometimes prepared at non-standard concentrations, which means the dose-volume conversion is different from branded. Read the label carefully.
- Stability. Compounded preparations have shorter beyond-use dates than commercially manufactured branded products.
Real-world weight loss in our reader survey, 2026 sample (n=400+), shows compounded semaglutide patients losing on average 12–14% of starting body weight at 12 months — modestly less than the 15% trial number for branded Wegovy at 72 weeks. Most of the gap is dose-escalation discipline, not efficacy of the molecule.
Safety considerations
The biggest variable is the pharmacy. A reputable 503A pharmacy will:
- Be registered with the state board of pharmacy and listed publicly.
- Source API from FDA-registered suppliers.
- Provide a certificate of analysis on request.
- Have no recent enforcement actions.
Ask your provider for the pharmacy name and confirm independently. Reputable telehealth platforms disclose this without resistance.
Cost difference
- Branded Wegovy/Zepbound, self-pay: $1,000–$1,300/month.
- Compounded semaglutide: $199–$349/month.
- Compounded tirzepatide: $349–$499/month.
The shortage cliff
This is the part most readers do not yet know. The FDA officially declared the tirzepatide shortage resolved in late 2024, with 503A compounding required to wind down within a defined window. The semaglutide shortage status is under similar review. When a shortage is officially resolved, legal compounding generally stops within months. If you are starting compounded GLP-1 in 2026, plan for the possibility of a forced switch to branded medication.